2021-01-11

Department of Neurology, Hubei Provincial Hospital of Integrated Chinese and Western Medicine, Hubei University of Chinese Medicine, 430000, Wuhan, China. fb98@163.com.; Department of Neurology, Hubei Provincial Hospital of Integrated Chinese and Western Medicine, Hubei University of Chinese Medicine, 430000, Wuhan, China.; Department of Neurology, Hubei Provincial Hospital of Integrated Chinese and Western Medicine, Hubei University of Chinese Medicine, 430000, Wuhan, China. liping332008@126.com.

BACKGROUND: The COVID-19 pandemic, which broke out in Wuhan in 2019, has become the global health crisis of our time. Elderly patients with certain fundamental diseases are more likely to develop severe cases. The secondary lesion following viral infection have only rarely been reported. CASE PRESENTATION: We here report two cases of coronavirus-infected pneumonia with acute ischemic stroke in middle-aged patients. In both COVID-19 cases, neurological physical examinations showed normal results before infection. Lymphocytopenia, accompanied by elevated cytokines and D-dimers, were found from serum clinical laboratory examination at admission. Dysarthria and limb muscle weakness are initial manifestations, occurring one week after infect-causative pathogen, SARS-CoV-2. The head CT and head/neck arterial CTA showed small-vessel occlusion. The patients were diagnosed with coronavirus diseases with secondary acute ischemic stroke. They were treated with tirofiban and followed up with

Department of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, China.; Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, China.; Department of Pulmonary and Critical Care Medicine, Shengjing Hospital of China Medical University, Shenyang, China.

Since December 2019, a novel coronavirus that caused viral pneumonia broke out and became global pandemic. Coronavirus disease 2019 (COVID-19) is caused by the SARS-CoV-2 virus. Reports on the clinical manifestations in solid organ transplant (SOT) recipients are rare. We report the clinical features and treatment of a Chinese renal transplant recipient with COVID-19. A 46-year-old Chinese woman, who had a renal transplant in 2006 due to chronic glomerulonephritis, was admitted to Renmin Hospital of Wuhan University for fever, cough, and expectoration for more than 10 days and diarrhea for 3 days. At admission, her body temperature was 38.2 °C and pulse oxygen saturation was 96% under oxygen inhalation. There were decreased breath sounds bilaterally. Laboratory data revealed normal leucocyte count, a normal percentage of neutrophils, a normal percentage of lymphocytes, decreased lymphocyte count, elevated procalcitonin and C-reactive protein (CRP), and increased levels of urea

2021-06-22

Frontiers Science Center for Flexible Electronics (FSCFE), Xian Institute of Flexible Electronics (IFE) & Xi'an Institute of Biomedical Materials and Engineering (IBME), Northwestern Polytechnical University (NPU), Xi'an 710072, China.; Frontiers Science Center for Flexible Electronics (FSCFE), Xian Institute of Flexible Electronics (IFE) & Xi'an Institute of Biomedical Materials and Engineering (IBME), Northwestern Polytechnical University (NPU), Xi'an 710072, China.; NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, 102206 Beijing, China.; Frontiers Science Center for Flexible Electronics (FSCFE), Xian Institute of Flexible Electronics (IFE) & Xi'an Institute of Biomedical Materials and Engineering (IBME), Northwestern Polytechnical University (NPU), Xi'an 710072, China.; Frontiers Science Center for Flexible Electronics (FSCFE), Xian Institute of Flexible Electronics (IFE) & Xi'an Institute of Biomedical Materials and Engineering (IBME), Northwestern Polytechnical University (NPU), Xi'an 710072, China.; Key Laboratory of Flexible Electronics (KLOFE) & Institute of Advanced Materials (IAM), Jiangsu National Synergetic Innovation Center for Advanced Materials (SICAM), Nanjing Tech University (NanjingTech), Nanjing 211816, China.; Key Laboratory for Organic Electronics and Information Displays (KLOEID) and Institute of Advanced Materials (IAM), Nanjing University of Posts and Telecommunications (NUPT), Nanjing 210023, China.

The SARS-CoV-2 outbreak that emerged at the end of 2019 has affected more than 58 million people with more than 1.38 million deaths and has had an incalculable impact on the world . Extensive prevention and treatment measures have been implemented since the pandemic. In this Review, we summarize current understanding on the source, transmission characteristics, and pathogenic mechanism of SARS-CoV-2. We also detail the recent development of diagnostic methods and potential treatment strategies of COVID-19 with focus on the ongoing clinical trials of antibodies, vaccines, and inhibitors for combating the emerging coronavirus.

2021-08-12

Beijing Advanced Innovation Center for Structural Biology & Frontier Research Center for Biological Structure, Beijing, China; Tsinghua-Peking Center for Life Sciences, Beijing, China; School of Life Sciences, Tsinghua University, Beijing, China.; Beijing Advanced Innovation Center for Structural Biology & Frontier Research Center for Biological Structure, Beijing, China; Tsinghua-Peking Center for Life Sciences, Beijing, China; School of Life Sciences, Tsinghua University, Beijing, China.; School of Life Sciences, Tsinghua University, Beijing, China.; Beijing Advanced Innovation Center for Structural Biology & Frontier Research Center for Biological Structure, Beijing, China; School of Medicine, Tsinghua University, Beijing, China.; Beijing Advanced Innovation Center for Structural Biology & Frontier Research Center for Biological Structure, Beijing, China; Tsinghua-Peking Center for Life Sciences, Beijing, China; School of Life Sciences, Tsinghua University, Beijing, China.; Beijing Advanced Innovation Center for Structural Biology & Frontier Research Center for Biological Structure, Beijing, China; School of Medicine, Tsinghua University, Beijing, China.; Beijing Advanced Innovation Center for Structural Biology & Frontier Research Center for Biological Structure, Beijing, China; Tsinghua-Peking Center for Life Sciences, Beijing, China; School of Life Sciences, Tsinghua University, Beijing, China. Electronic address: pilongli@mail.tsinghua.edu.cn.

Bearing a relatively large single-stranded RNA genome in nature, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) utilizes sophisticated replication/transcription complexes (RTCs), mainly composed of a network of nonstructural proteins and nucleocapsid protein, to establish efficient infection. In this study, we develop an innovative interaction screening strategy based on phase separation in cellulo, namely compartmentalization of protein-protein interactions in cells (CoPIC). Utilizing CoPIC screening, we map the interaction network among RTC-related viral proteins. We identify a total of 47 binary interactions among 14 proteins governing replication, discontinuous transcription, and translation of coronaviruses. Further exploration via CoPIC leads to the discovery of extensive ternary complexes composed of these components, which infer potential higher-order complexes. Taken together, our results present an efficient and robust interaction screening strategy, and they

2021-02-14

Hugh Kaul Precision Medicine Institute, University of Alabama at Birmingham, Birmingham, AL, United States.; Comprehensive Diabetes Center, Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Alabama at Birmingham, Birmingham, AL, United States.; School of Nursing, University of Alabama at Birmingham, Birmingham, AL, United States.; Hugh Kaul Precision Medicine Institute, University of Alabama at Birmingham, Birmingham, AL, United States.; Comprehensive Diabetes Center, Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Alabama at Birmingham, Birmingham, AL, United States.; Comprehensive Diabetes Center, Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Alabama at Birmingham, Birmingham, AL, United States.

BACKGROUND: Coronavirus disease-2019 (COVID-19) is a growing pandemic with an increasing death toll that has been linked to various comorbidities as well as racial disparity. However, the specific characteristics of these at-risk populations are still not known and approaches to lower mortality are lacking. METHODS: We conducted a retrospective electronic health record data analysis of 25,326 subjects tested for COVID-19 between 2/25/20 and 6/22/20 at the University of Alabama at Birmingham Hospital, a tertiary health care center in the racially diverse Southern U.S. The primary outcome was mortality in COVID-19-positive subjects and the association with subject characteristics and comorbidities was analyzed using simple and multiple linear logistic regression. RESULTS: The odds ratio of contracting COVID-19 was disproportionately high in Blacks/African-Americans (OR 2.6; 95% CI 2.19-3.10; p<0.0001) and in subjects with obesity (OR 1.93; 95% CI 1.64-2.28; p<0.0001), hypertension (OR

2021-11-22

Department of Biotechnology, Beijing Institute of Radiation Medicine, Beijing, China.; Department of Bio-security, Chinese PLA Center for Disease Control and Prevention, Beijing, China.; Department of Bio-security, Chinese PLA Center for Disease Control and Prevention, Beijing, China.; Graduate School, Academy of Military Medical Sciences, Beijing, China.; Department of Biotechnology, Beijing Institute of Radiation Medicine, Beijing, China.; Department of Bio-security, Chinese PLA Center for Disease Control and Prevention, Beijing, China.; Laboratory of Clinical Microbiology, Guangzhou Center for Disease Control and Prevention, Guangzhou, Guangdong, China.; Department of Bio-security, Chinese PLA Center for Disease Control and Prevention, Beijing, China.; Department of Biotechnology, Beijing Institute of Radiation Medicine, Beijing, China.

Genomic surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) plays an important role in COVID-19 pandemic control and elimination efforts, especially by elucidating its global transmission network and illustrating its viral evolution. The deployment of multiplex PCR assays that target SARS-CoV-2 followed by either massively parallel or nanopore sequencing is a widely-used strategy to obtain genome sequences from primary samples. However, multiplex PCR-based sequencing carries an inherent bias of sequencing depth among different amplicons, which may cause uneven coverage. Here we developed a two-pool, long-amplicon 36-plex PCR primer panel with ~1000-bp amplicon lengths for full-genome sequencing of SARS-CoV-2. We validated the panel by assessing nasopharyngeal swab samples with a <30 quantitative reverse transcription PCR cycle threshold value and found that ≥90% of viral genomes could be covered with high sequencing depths (≥20% mean depth). In comparison, the

2021-10-26

Zhoushan Center for Disease Control and Prevention, Zhoushan, China.; Zhoushan Center for Disease Control and Prevention, Zhoushan, China.; Zhoushan Center for Disease Control and Prevention, Zhoushan, China.; Zhoushan Center for Disease Control and Prevention, Zhoushan, China.; Zhoushan Center for Disease Control and Prevention, Zhoushan, China.; Zhoushan Center for Disease Control and Prevention, Zhoushan, China.; Zhoushan Center for Disease Control and Prevention, Zhoushan, China.; Zhoushan Center for Disease Control and Prevention, Zhoushan, China.; Zhoushan Center for Disease Control and Prevention, Zhoushan, China.

A cluster of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections was found in a cargo ship under repair in Zhoushan, China. Twelve of 20 crew members were identified as SARS-CoV-2 positive. We analyzed four sequences and identified them all in the Delta branch emerging from India with 7-8 amino acid mutation sites in the spike protein.CI - © 2021 Wiley Periodicals LLC.

2021-05-17

Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi'an Jiaotong University, Xi'an, China.; Center for Drug Safety and Policy Research, Xi'an Jiaotong University, Xi'an, China.; Shaanxi Center for Health Reform and Development Research, Xi'an, China.; Research Institute for Drug Safety and Monitoring, Institute of Pharmaceutical Science and Technology, Western China Science & Technology Innovation Harbor, Xi'an, China.; Department of Pharmacy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.; Department of Non-communicable Chronic Disease Control and Prevention, Shaanxi Provincial Center for Disease Control and Prevention, Xi'an, China.; Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi'an Jiaotong University, Xi'an, China.; Center for Drug Safety and Policy Research, Xi'an Jiaotong University, Xi'an, China.; Shaanxi Center for Health Reform and Development Research, Xi'an, China.; Research Institute for Drug Safety and Monitoring, Institute of Pharmaceutical Science and Technology, Western China Science & Technology Innovation Harbor, Xi'an, China.; Department of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, China.; Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi'an Jiaotong University, Xi'an, China.; Center for Drug Safety and Policy Research, Xi'an Jiaotong University, Xi'an, China.; Shaanxi Center for Health Reform and Development Research, Xi'an, China.; Research Institute for Drug Safety and Monitoring, Institute of Pharmaceutical Science and Technology, Western China Science & Technology Innovation Harbor, Xi'an, China.; Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi'an Jiaotong University, Xi'an, China.; Center for Drug Safety and Policy Research, Xi'an Jiaotong University, Xi'an, China.; Shaanxi Center for Health Reform and Development Research, Xi'an, China.; Research Institute for Drug Safety and Monitoring, Institute of Pharmaceutical Science and Technology, Western China Science & Technology Innovation Harbor, Xi'an, China.; Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi'an Jiaotong University, Xi'an, China.; Center for Drug Safety and Policy Research, Xi'an Jiaotong University, Xi'an, China.; Shaanxi Center for Health Reform and Development Research, Xi'an, China.; Research Institute for Drug Safety and Monitoring, Institute of Pharmaceutical Science and Technology, Western China Science & Technology Innovation Harbor, Xi'an, China.; Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi'an Jiaotong University, Xi'an, China.; Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi'an Jiaotong University, Xi'an, China.; Center for Drug Safety and Policy Research, Xi'an Jiaotong University, Xi'an, China.; Shaanxi Center for Health Reform and Development Research, Xi'an, China.; Research Institute for Drug Safety and Monitoring, Institute of Pharmaceutical Science and Technology, Western China Science & Technology Innovation Harbor, Xi'an, China.

The epidemic of coronavirus disease 2019 (COVID-19) broke out during the peak season of influenza in China. We aimed to assess the knowledge, attitudes, and practices (KAP) of influenza among Chinese adults during this special season. A cross-sectional online questionnaire survey was performed by recruiting 4822 participants. There were 76.09% of the participants reporting that they learned more knowledge of influenza during the COVID-19 epidemic. The mean knowledge score of participants was 5.51 ± 1.55 (78.7% correct rate), and participants who received influenza vaccination in the past year scored the highest (6.06 ± 1.30, p< .001). Nearly half of the participants (49.63%) agreed the threat to the functioning of society by influenza was far less than the COVID-19. 73.04% of the participants knew influenza vaccination was the most effective way to prevent influenza infection, while 54.18% did not know the vaccination location. The proportion of participants who were willing to get

Department of Cardiology, Changhai Hospital, Naval Medical University, Shanghai, China.; Department of Cardiology, Changhai Hospital, Naval Medical University, Shanghai, China.; Department of General Surgery, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.; Department of Cardiology, Changhai Hospital, Naval Medical University, Shanghai, China.; Department of Cardiology, Changhai Hospital, Naval Medical University, Shanghai, China.; Department of Cardiology, Changhai Hospital, Naval Medical University, Shanghai, China.; Department of Cardiology, Changhai Hospital, Naval Medical University, Shanghai, China.; Department of Cardiology, Changhai Hospital, Naval Medical University, Shanghai, China.; Department of Cardiology, Changhai Hospital, Naval Medical University, Shanghai, China.; Department of Cardiology, Changhai Hospital, Naval Medical University, Shanghai, China.

Objective: Cardiac injury is detected in numerous patients with coronavirus disease 2019 (COVID-19) and has been demonstrated to be closely related to poor outcomes. However, an optimal cardiac biomarker for predicting COVID-19 prognosis has not been identified. Methods: The PubMed, Web of Science, and Embase databases were searched for published articles between December 1, 2019 and September 8, 2021. Eligible studies that examined the anomalies of different cardiac biomarkers in patients with COVID-19 were included. The prevalence and odds ratios (ORs) were extracted. Summary estimates and the corresponding 95% confidence intervals (95% CIs) were obtained through meta-analyses. Results: A total of 63 studies, with 64,319 patients with COVID-19, were enrolled in this meta-analysis. The prevalence of elevated cardiac troponin I (cTnI) and myoglobin (Mb) in the general population with COVID-19 was 22.9 (19-27%) and 13.5% (10.6-16.4%), respectively. However, the presence of elevated Mb

2021-12-08

Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.; Key Laboratory of Heavy Ion Radiation Biology and Medicine of Chinese Academy of Sciences, Lanzhou, China.; Gansu Provincial Key Laboratory of Basic Research on Heavy Ion Radiation Application in Medicine, Lanzhou, China.; Lanzhou Heavy Ion Hospital, Lanzhou, China.; Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.; Key Laboratory of Heavy Ion Radiation Biology and Medicine of Chinese Academy of Sciences, Lanzhou, China.; Gansu Provincial Key Laboratory of Basic Research on Heavy Ion Radiation Application in Medicine, Lanzhou, China.; University of Chinese Academy of Sciences, Beijing, China.; Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.; Lanzhou Heavy Ion Hospital, Lanzhou, China.; Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.; Key Laboratory of Heavy Ion Radiation Biology and Medicine of Chinese Academy of Sciences, Lanzhou, China.; Gansu Provincial Key Laboratory of Basic Research on Heavy Ion Radiation Application in Medicine, Lanzhou, China.; University of Chinese Academy of Sciences, Beijing, China.; Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.; Key Laboratory of Heavy Ion Radiation Biology and Medicine of Chinese Academy of Sciences, Lanzhou, China.; Gansu Provincial Key Laboratory of Basic Research on Heavy Ion Radiation Application in Medicine, Lanzhou, China.; University of Chinese Academy of Sciences, Beijing, China.; Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.; Key Laboratory of Heavy Ion Radiation Biology and Medicine of Chinese Academy of Sciences, Lanzhou, China.; Gansu Provincial Key Laboratory of Basic Research on Heavy Ion Radiation Application in Medicine, Lanzhou, China.; University of Chinese Academy of Sciences, Beijing, China.; Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.; Key Laboratory of Heavy Ion Radiation Biology and Medicine of Chinese Academy of Sciences, Lanzhou, China.; Gansu Provincial Key Laboratory of Basic Research on Heavy Ion Radiation Application in Medicine, Lanzhou, China.; University of Chinese Academy of Sciences, Beijing, China.; Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.; Key Laboratory of Heavy Ion Radiation Biology and Medicine of Chinese Academy of Sciences, Lanzhou, China.; Gansu Provincial Key Laboratory of Basic Research on Heavy Ion Radiation Application in Medicine, Lanzhou, China.; University of Chinese Academy of Sciences, Beijing, China.; Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.; Key Laboratory of Heavy Ion Radiation Biology and Medicine of Chinese Academy of Sciences, Lanzhou, China.; Gansu Provincial Key Laboratory of Basic Research on Heavy Ion Radiation Application in Medicine, Lanzhou, China.; University of Chinese Academy of Sciences, Beijing, China.; Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.; Key Laboratory of Heavy Ion Radiation Biology and Medicine of Chinese Academy of Sciences, Lanzhou, China.; Gansu Provincial Key Laboratory of Basic Research on Heavy Ion Radiation Application in Medicine, Lanzhou, China.; University of Chinese Academy of Sciences, Beijing, China.; Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.; Key Laboratory of Heavy Ion Radiation Biology and Medicine of Chinese Academy of Sciences, Lanzhou, China.; Gansu Provincial Key Laboratory of Basic Research on Heavy Ion Radiation Application in Medicine, Lanzhou, China.; University of Chinese Academy of Sciences, Beijing, China.; Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.; Key Laboratory of Heavy Ion Radiation Biology and Medicine of Chinese Academy of Sciences, Lanzhou, China.; Gansu Provincial Key Laboratory of Basic Research on Heavy Ion Radiation Application in Medicine, Lanzhou, China.; University of Chinese Academy of Sciences, Beijing, China.; Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.; Lanzhou Heavy Ion Hospital, Lanzhou, China.; Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.; Lanzhou Heavy Ion Hospital, Lanzhou, China.; Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.; Lanzhou Heavy Ion Hospital, Lanzhou, China.

BACKGROUND AND AIMS: The existing evidence has indicated that hyperthermia ablation (HA) and HA combined with transarterial chemoembolization (HATACE) are the optimal alternative to surgical resection for patients with hepatocellular carcinoma (HCC) in the COVID-19 crisis. However, the evidence for decision-making is lacking in terms of comparison between HA and HATACE. Herein, a comprehensive evaluation was performed to compare the efficacy and safety of HATACE with monotherapy. MATERIALS AND METHODS: Worldwide studies were collected to evaluate the HATACE regimen for HCC due to the practical need for global extrapolation of applicative population. Meta-analyses were performed using the RevMan 5.3 software (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). RESULTS: Thirty-six studies involving a large sample of 5036 patients were included finally. Compared with HA alone, HATACE produced the advantage of 5-year overall survival (OS) rate (OR:1.90; 95%CI: